This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Lumiliximab

Biogen, Inc.

Drug Names(s): Anti-CD23 mAb, IDEC-152

Description: IDEC-152 is a primatized monoclonal antibodythat targets the CD23 marker on specific immunecells. It has been well documented thatinterference with CD23 can inhibit the productionof Immunoglobulin E (IgE), the type of antibodythat contributes to asthma and various allergicdisorders.

Deal Structure: On April 25, 2002, IDEC extended its collaborative research agreement with Seikagaku Corporation to support the clinical development of IDEC-152. Financial terms of the entire collaborative agreement, including the extension, are valued at approximately $60 million.

Partners: Seikagaku Corporation


Lumiliximab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug